Personalized Medicine · 2018 · 33 citations · 21 references
MedicinePharmacoeconomicsPsychiatryPharmacogeneticsPharmacogenomicsPsychopharmacologyClinical Implementation Of PharmacogeneticsClinical Implementation Of PharmacogenomicsHealthcare Cost AnalysisPharmacoeconomic EvaluationPsychiatric PharmacogenomicsAdministrative Claims DataAdministrative Claims Data AnalysisClinical Utility Of Pharmacogenomic TestingDrug Cost AnalysisHealth Economics Of PharmacogenomicsHealth Plan ComparisonPharmacogenetic-guided PrescribingPharmacogenomics Of Psychotropic Drugs
AIM: To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU). PATIENTS & METHODS: cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods. RESULTS: 205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a per-member-per-month savings of US$0.07. Disease-specific analyses resulted in similar savings. CONCLUSION: Use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations.
21
Avshalom Caspi, Renate Houts, Daniel W. Belsky et al. · Clinical Psychological Science · 2013 · 2.5K citations · Full text
J. C. Barker, M. David Enoch · BMJ · 1964 · 258 citations · Full text
Michael Bauer, Emanuel Severus, Stephan Köhler et al. · The World Journal of Biological Psychiatry · 2015 · 197 citations